Funder
Asahi Kasei Pharma Corporation
Nippon Shinyaku
Astellas Pharma
AbbVie
Otsuka Pharmaceutical
Takeda Pharmaceutical Company
Novartis
Janssen Japan
Publisher
Springer Science and Business Media LLC
Reference115 articles.
1. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927–74.
2. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23:e334–47.
3. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41:3063–71.
4. National Comprehensive Cancer Network. Cancer-Associated Venous Thromboembolic Disease (Version 2.2023) [Internet]. National Comprehensive Cancer Network; 2023 Jun. Report No.: Version 2.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
5. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959–69.